Why the study?
Cognitive impairment is common in heart failure, but its association with biomarkers related to heart failure or cognitive decline remains unclear.
Cohort (n=145)
No
Hazard Ratio: 1.42 (95% CI 1.17–1.73)
p-value: p=<0.001
In patients hospitalized for acute decompensated HFrEF, GDF-15 predicts cognitive impairment and is associated with worse clinical outcomes.
GDF-15 may aid cognitive risk stratification in HFrEF; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: Cognitive impairment (CI) is common in patients with heart failure (HF), but the association between CI and biomarkers related to HF or cognitive decline in patients with HF remains unclear. METHODS: This prospective observational study investigated the incidence of CI, subsequent cognitive changes, and the association between CI and novel biomarkers in patients with left ventricular ejection fraction < 40% who were hospitalized for acute decompensated HF. Patients were evaluated for CI, depressive symptoms, and quality of life with the Mini-Mental State Examination (MMSE) and the Mini-Cog, Beck Depression Inventory (BDI)-II, and Kansas City Cardiomyopathy Questionnaire (KCCQ), respectively. The primary endpoint was a composite of all-cause mortality or hospitalization for HF at one year. RESULTS: < 0.001). CONCLUSIONS: In patients with HF with CI, cognitive function, depression, and quality of life measures improved at the 3-month and 1-year follow-up. GDF-15 predicted CI with moderate discrimination capacity and was associated with worse HF outcomes.
No takes yet. Share an insight, caveat, or question.
Tung et al. (2022) conducted a cohort in Acute decompensated heart failure (n=145). GDF-15 vs. Lower GDF-15 levels was evaluated on Composite of all-cause mortality or hospitalization for heart failure at 1 year (HR 1.42, 95% CI 1.17-1.73, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: